Changing the tumor microenvironment from immunosuppressive to immunostimulatory holds the biggest promise for more effective tumor therapies as is attested with recent successes of the anti-PD-L1 treatment, which however met with limited success in CRC patients. Here, CD274 is linked to colorectal carcinoma.